Eli Lilly on Tuesday raised its full-year guidance as second-quarter profit jumped 85% from the same period a year ago on strong sales from the pharmaceutical giant's diabetes treatment Mounjaro and other drugs.
The company now expects full-year revenue of between $33.4 billion and $33.9 billion, up from a previous forecast of $31.2 billion to $31.7 billion. Eli Lilly also increased its adjusted earnings guidance to a range of $9.70 to $9.90 per share for the year, up from a range of $8.65 to $8.85.
Shares of Eli Lilly surged 14% Tuesday.
Eli Lilly beat Wall Street expectations:
- Adjusted earnings: $2.11 per share, vs. $1.98 per share expected
- Revenue: $8.31 billion, vs. $7.58 billion expected
Accounting for charges associated with some intangible assets and losses on securities, the company recorded adjusted income of $1.9 billion, or $2.11 per share.
The company's $8.31 billion in sales for the quarter marked a 28% increase from the same period a year ago.
Drug results
Revenue growth was also driven by sales of breast cancer pill Verzenio, which rose 57% to $926.8 million for the quarter. Sales of Jardiance, a tablet that lowers blood sugar in Type 2 diabetes patients, climbed 45% to $668.3 million for the second quarter.
Newer drugs like Mounjaro, the company's Type 2 diabetes injection, also fueled revenue growth, posting $979.7 million in sales for the quarter. The drug was first approved in the U.S. in May 2022 and notched just $16 million in sales in the year-ago period.
Investors have pinned high hopes on Mounjaro's potential mega-blockbuster trajectory beyond diabetes, with some research suggesting that it may be even more effective at reducing weight than Novo Nordisk's popular Wegovy and Ozempic injections.
Last month, Eli Lilly filed for Food and Drug Administration approval of the injection for chronic weight management.
Eli Lilly said it "has experienced and continues to expect intermittent delays fulfilling orders of certain Mounjaro doses given significant demand."
Pipeline and acquisitions
Eli Lilly's stock has been on a tear in recent months, driven in part by positive trial results for its Alzheimer's drug, donanemab, and the company's progress with its promising obesity drug pipeline.
Shares of Eli Lilly are up more than 24% for the year. With a market value of roughly $431 billion, Eli Lilly is the second-largest pharmaceutical company based in the U.S. after Johnson & Johnson.
Eli Lilly in July announced a $1.93 billion deal to buy Versanis, a privately held obesity drug maker.
[link] [comments] https://www.reddit.com/r/stocks/comments/15lj4vh/eli_lilly_raises_fullyear_guidance_as_mounjaro/
Accedi per aggiungere un commento
Altri post in questo gruppo
Please use this thread to discuss your portfolio, learn of other stock tickers, and help out users by giving constructive criticism.
Why quarterly? Public comp
When you sell a stock to buy another stock, do you prefer to set the estimated amount of the capital gains taxes aside in a money market or do you think it better to
Saving for retirement is crucial, but relying solely on a 401(k) might not be enough due to high inflation. Consider investing in growth stocks, especially in the tec
I’m think this is not a good investment as there is no chatter at all on the 52 week low. They are involved in a class action lawsuits by investors and credit card co
Sorry if this is the wrong sub. Let’s say I had $1 million in VOO but I wanted to sell half of it to buy SCHD. It would suck to pay taxes on $500k. So how would you g
Hey guys, I did a deep dive into Crocs. In this analysis, I will do a brief breakdown of the company and go over some quantitative data, qualitative data and estimate
